Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential SBRT with S1 and Endostar for Stage IV Lung Squamous Cell Carcinoma
NCT04274270Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Apr 2020
- Primary completion
- Jan 2022
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Open-label, single-arm trial of endostar in squamous cell carcinoma of the lung (LSCC), sponsored by Peking University Third Hospital. Primary endpoints: Overall Survival at 3 years and Progression-Free Survival. Status: unknown.
02
Drugs
endostar
03
Conditions
squamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT04274270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04274270.